GCCs to Drive Nearly Half of India's Office Leasing by 2026
Source: ET Fintech & Tech
Arth Insight · What this means for your wallet
- Increased demand for office space from GCCs could boost rental yields for commercial properties, potentially increasing returns on real estate investments.
- This trend signals strong economic activity and job creation, which can indirectly benefit your overall financial well-being through a stronger economy.
- While direct investment in commercial real estate is complex, indirect exposure through diversified funds offers a way to participate in this growth.
Global Capability Centres (GCCs) are set to dominate India's office leasing market, potentially accounting for almost half of all space leased by 2026. In the first half of 2026, GCCs leased 16.6 million sq ft of Grade A office space, representing 46% of total leasing across seven major Indian cities.
- ▸GCCs leased 16.6 million sq ft of office space in H1 2026.
- ▸GCCs accounted for 46% of total office leasing in top 7 cities.
- ▸GCCs are projected to drive nearly half of India's office leasing by 2026.
- ▸This trend indicates strong demand for Grade A office spaces.
- ✓GCCs leased 16.6 million sq ft of office space in H1 2026.
- ✓GCCs accounted for 46% of total office leasing in top 7 cities.
- ✓GCCs are projected to drive nearly half of India's office leasing by 2026.
- ✓This trend indicates strong demand for Grade A office spaces.
India's office market is showing remarkable resilience, with Global Capability Centres (GCCs) playing an increasingly significant role in leasing activities. A recent report indicates that GCCs are poised to become the primary drivers of office space demand in the country.
During the first half of 2026, GCCs collectively leased a substantial 16.6 million square feet of Grade A office space. This volume represented a significant 46% of the total office leasing across India's top seven cities, highlighting their growing influence.
The report suggests this trend is likely to continue, with GCCs potentially accounting for nearly half of all office leasing in India by 2026. This sustained demand from GCCs underscores their strategic importance to the Indian commercial real estate sector.
The robust performance of GCCs in leasing office space reflects their continued expansion and investment in India. These centres, often subsidiaries of multinational corporations, provide a range of services including IT, R&D, and business process outsourcing.
The increasing share of GCCs in office leasing signals a positive outlook for the commercial real estate market. It suggests continued job creation and economic activity supported by these global entities. Developers and property managers are likely to see sustained demand for high-quality office spaces, particularly in major metropolitan areas.
This report is for informational purposes only and does not constitute investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What are Global Capability Centres (GCCs)?
GCCs are offshore centres set up by multinational corporations in countries like India to perform various business functions, including IT services, research and development, and business process outsourcing.
Which cities are considered the top seven in India for office leasing?
Typically, the top seven cities include Mumbai, Delhi NCR, Bengaluru, Hyderabad, Pune, Chennai, and Kolkata.
What does 'Grade A' office space refer to?
Grade A office space denotes premium, high-quality buildings in prime locations, offering modern amenities, good infrastructure, and professional management.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Related Stories
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.